Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:36 AM
Ignite Modification Date:
2025-12-25 @ 2:36 AM
NCT ID:
NCT00216034
Eligibility Criteria:
Inclusion Criteria:
* Patients with microscopic stage II or IIIA resectable gastric cancer
* Patients who have not received preoperative cancer therapy (radiotherapy, chemotherapy or immunotherapy)
* Patients with serum immunosuppressive acidic protein (IAP) measured within 2 weeks before surgery
* Patients with no metachronous or synchronous multiple cancer
* Patients without severe impairment of renal, hepatic and bone marrow functions
* Patients who are judged to be capable of tolerating surgery
* Patients with preoperative performance status 0 to 2
* Patients with no serious concurrent complications (such as bone marrow suppression, diarrhea and infection)
* Patients who are judged to be capable of tolerating this treatment, and who have given written informed consent to participate in this study
Exclusion Criteria:
* Patients with fresh hemorrhage from the gastrointestinal tract
* Patients with retention of body fluid necessitating treatment
* Patients with infection, intestinal palsy or intestinal occlusion
* Patients who are pregnant or hope to become pregnant during the study period
* Patients with diabetes treated by continuous use of insulin or showing poor glycemic control
* Patients with a history of ischemic heart disease
* Patients with concurrent psychiatric disease or psychotic symptoms, and judged to have difficulties participating in the study
* Patients receiving continuous administration of steroids
* Patients who have experienced serious drug allergy in the past
* Others, patients judged by the investigator or subinvestigator to be inappropriate as subject
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
80 Years
Study:
NCT00216034
Study Brief:
Protocol Section:
NCT00216034